Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Excelling at Discussion: Genuine Examples of overcoming adversity - 2Crew-11 astronauts undock in 1st-ever medical evacuation from the International Space Station (video)
- 3Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- 421 Things You Ought to Never Tell Your Childless Companion
- 5Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- A definitive Manual for Internet Mastering and Expertise Improvement
- Staggering Spots to Stargaze All over the Planet
- Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- 'Wicked: For Good' was filmed at this surreal National Park in Egypt
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Motivational Travel Objections for History Buffs
- In these U.S. groups, deaths now exceed births. What’s happening?
